Clinical Advances and New Insights in Systemic Sclerosis

A special issue of Sclerosis (ISSN 2813-3064).

Deadline for manuscript submissions: 20 December 2025 | Viewed by 163

Special Issue Editor


E-Mail Website
Guest Editor
Department of Microbiology & Immunology, College of Medicine, Drexel University, Philadelphia, PA 19129, USA
Interests: systemic sclerosis (scleroderma); fibrosis; inflammasome signaling; collagen export from the endoplasmic reticulum; small molecule therapeutic development

Special Issue Information

Dear Colleagues,

Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune disease marked by widespread fibrosis of the skin and organs, vascular abnormalities, and immune dysregulation. Despite progress in our understanding of its mechanisms, effective treatments remain limited.

This Special Issue, "Clinical Advances and New Insights in Systemic Sclerosis", aims to highlight recent clinical breakthroughs, research developments, and emerging therapies for SSc. We invite submissions addressing early diagnosis, enhanced management, and patient-specific treatments, with the aim of offering a comprehensive overview of current and future SSc care. Submissions may cover a range of topics including, but not limited to, the following:

  • Pathophysiology: The mechanisms driving fibrosis, immune dysfunction, and vascular changes.
  • Early Diagnosis: New tools and biomarkers for the early detection of SSc.
  • Clinical Subtypes: SSc phenotypes and personalized treatment strategies.
  • Treatments: Advances in biologics, immunosuppression, and non-pharmacologic approaches.
  • Long-Term Care: Managing complications and improving patient outcomes.
  • Future Research: Novel therapies, biomarkers, and personalized medicine.

Dr. Carol M. Artlett
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sclerosis is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • systemic sclerosis
  • scleroderma
  • fibrosis
  • biomarkers
  • personalized treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 405 KiB  
Article
Identifying Patients with Systemic Sclerosis and Progressive Pulmonary Fibrosis in a Real-World Setting: Data from UK Tertiary Rheumatology and ILD Centres
by Rosalind Benson, Mahin Ahmad, Lisa G. Spencer, Freddy Frost, Madhu Paravasthu and Theresa Barnes
Sclerosis 2025, 3(3), 25; https://doi.org/10.3390/sclerosis3030025 - 1 Jul 2025
Abstract
Objectives: Systemic sclerosis-related interstitial lung disease (SSc-ILD) has high associated morbidity and mortality. With early diagnosis and treatment, we can improve clinical outcomes with immunosuppression. Some patients develop progressive pulmonary fibrosis (PPF) and are eligible for anti-fibrotic therapy. There are limited data on [...] Read more.
Objectives: Systemic sclerosis-related interstitial lung disease (SSc-ILD) has high associated morbidity and mortality. With early diagnosis and treatment, we can improve clinical outcomes with immunosuppression. Some patients develop progressive pulmonary fibrosis (PPF) and are eligible for anti-fibrotic therapy. There are limited data on the incidence and prevalence of PPF in the SSc ILD cohort to guide case finding. We investigated this using data from UK tertiary Rheumatology and ILD centres. Methods: Patients with systemic sclerosis across two UK rheumatology units were identified using electronic records searched from 2021 to 2023 and were compared against established PPF diagnostic criteria. Results: 255 patients were identified. Prevalence of PPF was 5.49% and in those with established SSc-ILD, 23%. Median time to development of PPF was 5 years. In 64% of patients with PPF diagnosis, they had had systemic sclerosis for over 10 years. Incidence of PPF in patients with SSc was 3.9% and in those with known SSc-ILD 16.%. Only 50% of patients who met criteria for PPF had been referred to respiratory for consideration of antifibrotic initiation. Patients with a predominantly fibrotic baseline radiological pattern (UIP) had a trend towards development of PPF (p = 0.07). No patient with a predominantly inflammatory baseline pattern developed PPF (p = 0.021). Conclusions: Real world data have shown a prevalence of PPF in the SSc-ILD cohort of 23% with a median time of 5 years to development from diagnosis of SSc. Our data show active case finding may be incomplete and rheumatologists must be cognisant of PPF when evaluating patients with SSc. Full article
(This article belongs to the Special Issue Clinical Advances and New Insights in Systemic Sclerosis)
Show Figures

Figure 1

Back to TopTop